Azitra reports FY2023 net loss $11.3M, cash $1.8M; advances ATR-12 Phase 1b and ATR-04 IND

Azitra, Inc.

Net loss $11.3M vs $10.7M in 2022; service revenue from related party $0.7M.
Cash and equivalents $1.8M at Dec 31, 2023, plus $4.4M net from Feb 2024 follow-on.
ATR-12 for Netherton syndrome: Phase 1b trial enrolling ~12 patients; safety data in late 2024.
ATR-04 for EGFRi-associated rash: IND submission mid-2024; first-in-human trial by late 2024/early 2025.
Bayer joint development agreement progressing; expect license agreement with upfront payment.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Azitra, Inc. reported the full year ended December 31, 2023 results: revenue $0.7 million, net income $11.3 million.

Period: the full year ended December 31, 2023
Revenue: $0.7 million
Net income: $11.3 million
Result: reported results

Exact text from the filing

■ Execution of a licensing agreement with upfront payment Financial Results for the Year Ended December 31, 2023 ● Service Revenue – Related Party : The Company generated $0.7 million of service revenue during the year ended December 31, 2023, compared to $0.3 million for the comparable period in 2022. ● Research and Development (R&D) expenses : R&D

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Azitra, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-010097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.